Agonists acting on m-opioid receptors (MOR) are very effective analgesics but cause tolerance during long-term or repeated exposure. Intensive efforts have been made to find novel opioid agonists that are efficacious analgesics but can elude the signalling events that cause tolerance. m-Opioid agonists differentially couple to downstream signalling mechanisms. Some agonists, such as enkephalins, ,N-Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO), methadone and sufentanyl are efficacious at mediating G-protein and effector coupling, as well as triggering MOR regulatory events that include MOR phosphorylation, b-arrestin binding, receptor endocytosis and recycling. By contrast, morphine and closely related alkaloids can mediate efficacious MOR-effector coupling but poorly trigger receptor regulation. Several models have been proposed to relate differential MOR regulation by different opioids with their propensity to cause tolerance. Most are based on dogma that b-arrestin-2 (barr-2) binding causes MOR desensitization and/or that MOR endocytosis and recycling are required for receptor resensitization. This review will examine some of these notions in light of recent evidence establishing that MOR dephosphorylation and resensitization do not require endocytosis. Recent evidence from opioid-treated animals also suggests that impaired MOR-effector coupling is driven, at least in part, by enhanced desensitization, as well as impaired resensitization that appears to be barr-2 dependent. Better understanding of how chronic exposure to opioids alters receptor regulatory mechanisms may facilitate the development of effective analgesics that produce limited tolerance.
LINKED ARTICLESThis
IntroductionOpioids are potent and effective analgesics. It is well established that nearly all clinically used opioids mediate their analgesic effects by activating the m-opioid receptor (MOR; Kieffer and Gaveriaux-Ruff, 2002). However, long-term use of m-opioid agonists produces adverse effects that include the development of tolerance and addiction, limiting their clinical utility (Williams et al., 2001;Christie, 2008;Morgan and Christie, 2011). Qualitatively, all MOR agonists produce tolerance in vivo although there are differences in the extent of tolerance (Morgan and Christie, 2011), suggesting that opioid analgesics resistant to tolerance could be developed. Recent promising approaches to limit tolerance have been extensively reviewed and include simultaneous activation of more than one opioid receptor type (e.g. MOR and DOR receptors), selective targeting of heteromultimers or opioids that differentially activate distinct intracellular signalling cascades, possibly involving differential activation of Ga subtypes (Pineyro and Archer-Lahlou, 2007), and particularly differential G-protein activation versus endocytosis (e.g. Martini and Whistler, 2007;Christie, 2008;Koch and Hollt, 2008;Berger and Whistler, 2010;von Zastrow, 2010).
BJPBritish Journal of Pharmacology DOI:10.1111DOI:10. /j.1476DOI:10. -5381.2011 1704 British Journal of Pharmac...